Analysis · Health
How Missing Fracture Data Can Complicate a Drug Comparison
By AWEI · AI-compiled · Published · Analysis prepared · 1 source · doi.org
A major osteoporosis trial can disappear from one part of a research review because its publication does not report the required outcome. That happened in a 2023 analysis: a pivotal denosumab trial could not contribute to the comparison of clinical fractures because the necessary combined fracture data were unavailable.
Mina Nicole Händel and colleagues, writing in The BMJ, reviewed 69 randomised trials involving more than 80,000 participants. They studied osteoporosis treatments in postmenopausal women, excluding trials conducted exclusively in Asian settings because dosing differed. Their central question concerned preventing fractures, rather than simply increasing bone density.
The team used network meta-analysis to compare treatments directly and indirectly. When two drugs had each been tested against placebo, that shared comparator helped estimate their relative effects. Such comparisons depend on the trials being sufficiently similar in characteristics that could influence treatment benefits.
The analysis supported reductions in clinical fractures with bisphosphonates, parathyroid hormone receptor agonists and romosozumab compared with placebo. It did not establish that benefit for denosumab on this particular outcome. Yet denosumab showed benefits for spinal and hip fractures. The missing clinical-fracture data mean its result on that endpoint cannot establish that the drug is ineffective.
Certainty across outcomes was moderate to low, reflecting reporting problems, potential bias and imprecise estimates. Fracture definitions also varied. A separate analysis linked older average participant age with greater relative benefit from antiresorptive drugs, but that was an observational comparison between trials. It cannot show that age itself caused a stronger response in individual women.
The practical lesson is to examine the outcome and the available evidence behind a treatment ranking. This review supports fracture prevention benefits for several therapies, while showing why an apparently unfavourable comparison may remain unresolved. Complete reporting and individual participant data would help clarify which differences are dependable and whom they apply to.
Sources used for this article (1)
Direct links to the publisher reports used to prepare this article.
- Source 1
- Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials ['Mina Nicole Händel', 'Isabel Cardoso', 'Cecilie von Bülow', 'Jeanett Friis Rohde', 'Anja Ussing', 'Sabrina Mai Nielsen', 'Robin Christensen', 'Jean‐Jacques Body', 'Maria Luisa Brandi', 'Adolfo Díez‐
